Monthly
US$200
Billed every month
Azilsartan Medoxomil Potassium Tablets(美阿沙坦钾片)
Companies, stages and changes, with each record available on this page.
Last 90 days: No longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders25View records ↓
Under-review filings33View records ↓
This year’s generic filers8View records ↓
NHSA approval numbers50View records ↓
API companies with A status13View records ↓
Chemical-drug catalogue
Loaded records: 25 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 24 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 珠海润都制药股份有限公司 | 珠海润都制药股份有限公司 | 国药准字H20265138 | 2026/07/08 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 珠海润都制药股份有限公司 | 珠海润都制药股份有限公司 | 国药准字H20265137 | 2026/07/08 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20265038 | 2026/06/30 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20265037 | 2026/06/30 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京民康百草医药科技有限公司 | 赤峰赛林泰药业有限公司 | 国药准字H20264859 | 2026/06/17 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京民康百草医药科技有限公司 | 赤峰赛林泰药业有限公司 | 国药准字H20264858 | 2026/06/17 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江尖峰药业有限公司 | 浙江尖峰药业有限公司 | 国药准字H20264463 | 2026/05/19 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥立方制药股份有限公司 | 合肥立方制药股份有限公司 | 国药准字H20264452 | 2026/05/19 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥立方制药股份有限公司 | 合肥立方制药股份有限公司 | 国药准字H20264453 | 2026/05/19 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江尖峰药业有限公司 | 浙江尖峰药业有限公司 | 国药准字H20264462 | 2026/05/19 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南赛立克药业有限公司 | 海南赛立克药业有限公司 | 国药准字H20264261 | 2026/05/07 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南赛立克药业有限公司 | 海南赛立克药业有限公司 | 国药准字H20264262 | 2026/05/07 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥国高药业有限公司 | 江苏和晨药业有限公司 | 国药准字H20264267 | 2026/05/07 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥国高药业有限公司 | 江苏和晨药业有限公司 | 国药准字H20264266 | 2026/05/07 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西白鹿制药股份有限公司 | 陕西白鹿制药股份有限公司 | 国药准字H20264151 | 2026/04/29 | 40mg(按C30H24N4O8计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西白鹿制药股份有限公司 | 陕西白鹿制药股份有限公司 | 国药准字H20264152 | 2026/04/29 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江高跖医药科技股份有限公司 | 浙江华润三九众益制药有限公司 | 国药准字H20264139 | 2026/04/21 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江高跖医药科技股份有限公司 | 浙江华润三九众益制药有限公司 | 国药准字H20264138 | 2026/04/21 | 40mg(按C30H24N4O8计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州市联瑞制药有限公司 | 广州市联瑞制药有限公司 | 国药准字H20264006 | 2026/04/14 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州市联瑞制药有限公司 | 广州市联瑞制药有限公司 | 国药准字H20264005 | 2026/04/14 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西施美药业股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20263309 | 2026/02/02 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西施美药业股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20263310 | 2026/02/02 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 新乡市常乐制药有限责任公司 | 新乡市常乐制药有限责任公司 | 国药准字H20256376 | 2025/12/22 | 40mg（ 按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 新乡市常乐制药有限责任公司 | 新乡市常乐制药有限责任公司 | 国药准字H20256375 | 2025/12/22 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20256241 | 2025/12/16 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20256242 | 2025/12/16 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 沐源（安徽）药业有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20255997 | 2025/11/18 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 沐源（安徽）药业有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20255998 | 2025/11/18 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南慧泽生物医药科技有限公司 | 湖南九典制药股份有限公司 | 国药准字H20255981 | 2025/11/18 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南慧泽生物医药科技有限公司 | 湖南九典制药股份有限公司 | 国药准字H20255982 | 2025/11/18 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 嘉亨（珠海横琴）医药科技有限公司 | 山东药石药业有限公司 | 国药准字H20255913 | 2025/11/12 | 按美阿沙坦（C30H24N4O8）计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 嘉亨（珠海横琴）医药科技有限公司 | 山东药石药业有限公司 | 国药准字H20255912 | 2025/11/12 | 按美阿沙坦（C30H24N4O8）计 80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏永安制药有限公司 | 江苏永安制药有限公司 | 国药准字H20255786 | 2025/10/21 | 按美阿沙坦（C30H24N4O8）计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏永安制药有限公司 | 江苏永安制药有限公司 | 国药准字H20255787 | 2025/10/21 | 按美阿沙坦（C30H24N4O8）计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20255689 | 2025/10/14 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20255688 | 2025/10/14 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20255630 | 2025/09/30 | 按美阿沙坦（C30H24N4O8）计80 mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20255631 | 2025/09/30 | 按美阿沙坦（C30H24N4O8）计 40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏和晨药业有限公司 | 江苏和晨药业有限公司 | 国药准字H20255268 | 2025/09/02 | 40mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏和晨药业有限公司 | 江苏和晨药业有限公司 | 国药准字H20255269 | 2025/09/02 | 80mg（按C30H24N4O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20254938 | 2025/07/22 | 按C30H24N4O8计40mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏联环药业股份有限公司 | 江苏联环药业股份有限公司 | 国药准字H20253694 | 2025/03/25 | 按美阿沙坦（C30H24N4O8）计80 mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏联环药业股份有限公司 | 江苏联环药业股份有限公司 | 国药准字H20253695 | 2025/03/25 | 按美阿沙坦（C30H24N4O8）计40 mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 桂林南药股份有限公司 | 山东朗诺制药有限公司 | 国药准字H20253641 | 2025/03/18 | 按美阿沙坦（C30H24N4O8）计40 mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 桂林南药股份有限公司 | 山东朗诺制药有限公司 | 国药准字H20253642 | 2025/03/18 | 按美阿沙坦（C30H24N4O8）计80 mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20244706 | 2024/08/20 | 40mg（按C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>8</sub>计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20244707 | 2024/08/20 | 80mg（按C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>8</sub>计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Takeda Pharma A/S | Takeda Ireland Ltd. | 国药准字HJ20210004 | 2021/01/19 | 按美阿沙坦（C30H24N4O8）计80 mg | Imported originator drug (进口原研药品) | CDE |
| Takeda Pharma A/S | Takeda Ireland Ltd. | 国药准字HJ20210003 | 2021/01/19 | 按美阿沙坦（C30H24N4O8）计40 mg | Imported originator drug (进口原研药品) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20254939 | 2025/07/22 | 按C30H24N4O8计80mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 50 distinct approval numbers and 25 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 国药准字H20244706 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010100177 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253695 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40 mg | Category B (乙) | XC09CAM175A001010101467 | NHSA |
| 陕西白鹿制药股份有限公司 | 国药准字H20264151 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010102353 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264856 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010102877 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20256376 | 40mg( 按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010103216 | NHSA |
| 合肥立方制药股份有限公司 | 国药准字H20264452 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010104394 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20255630 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80 mg | Category B (乙) | XC09CAM175A001010104606 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20264462 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010104655 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20253641 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40 mg | Category B (乙) | XC09CAM175A001010105206 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20263309 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001010105356 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20264261 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001010105805 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20255689 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010105847 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254938 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010109568 | NHSA |
| 江苏永安制药有限公司 | 国药准字H20255787 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001010179289 | NHSA |
| Takeda Pharma A/S | 国药准字HJ20210004 | 80mg(按C₃₀H₂₄N₄O₈计 ) | Category B (乙) | XC09CAM175A001010179422 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256241 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010183033 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20264006 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010183238 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010183521 | NHSA |
| 北京民康百草医药科技有限公司 | 国药准字H20264858 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001010183644 | NHSA |
| 杭州和泽坤元药业有限公司 | 国药准字H20255268 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010183879 | NHSA |
| 合肥国高药业有限公司 | 国药准字H20264266 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010183883 | NHSA |
| 湖南慧泽生物医药科技有限公司 | 国药准字H20255981 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010183916 | NHSA |
| 嘉亨(珠海横琴)医药科技有限公司 | 国药准字H20255913 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40mg | Category B (乙) | XC09CAM175A001010184183 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264138 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010184221 | NHSA |
| 沐源(安徽)药业有限公司 | 国药准字H20255998 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010184519 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20244706 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010200177 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253695 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40 mg | Category B (乙) | XC09CAM175A001010201467 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264856 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010202877 | NHSA |
| 合肥立方制药股份有限公司 | 国药准字H20264452 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010204394 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20253641 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40 mg | Category B (乙) | XC09CAM175A001010205206 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20264261 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001010205805 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254938 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010209568 | NHSA |
| 江苏永安制药有限公司 | 国药准字H20255787 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001010279289 | NHSA |
| Takeda Pharma A/S | 国药准字HJ20210003 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010279422 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256241 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010283033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010283521 | NHSA |
| 杭州和泽坤元药业有限公司 | 国药准字H20255268 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010283879 | NHSA |
| 合肥国高药业有限公司 | 国药准字H20264266 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010283883 | NHSA |
| 湖南慧泽生物医药科技有限公司 | 国药准字H20255981 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010283916 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253695 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40 mg | Category B (乙) | XC09CAM175A001010301467 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264856 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010302877 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254938 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010309568 | NHSA |
| 江苏永安制药有限公司 | 国药准字H20255787 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001010379289 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256241 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010383033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010383521 | NHSA |
| 杭州和泽坤元药业有限公司 | 国药准字H20255268 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010383879 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253695 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40 mg | Category B (乙) | XC09CAM175A001010401467 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264856 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010402877 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256241 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010483033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010483521 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256241 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001010583033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001010983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001011983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001012983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001013983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001014083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001014183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001014283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001014383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265037 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001014483521 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20244707 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020100177 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253694 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001020101467 | NHSA |
| 陕西白鹿制药股份有限公司 | 国药准字H20264152 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020102353 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264857 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020102877 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20256375 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020103216 | NHSA |
| 合肥立方制药股份有限公司 | 国药准字H20264453 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020104394 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20255631 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计 40mg | Category B (乙) | XC09CAM175A001020104606 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20264463 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020104655 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20253642 | 按美阿沙坦(C30H24N4O8计80 mg | Category B (乙) | XC09CAM175A001020105206 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20263310 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001020105356 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20264262 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001020105805 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20255688 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020105847 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254939 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020109568 | NHSA |
| 江苏永安制药有限公司 | 国药准字H20255786 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40mg | Category B (乙) | XC09CAM175A001020179289 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256242 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020183033 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20264005 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020183238 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020183521 | NHSA |
| 北京民康百草医药科技有限公司 | 国药准字H20264859 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001020183644 | NHSA |
| 杭州和泽坤元药业有限公司 | 国药准字H20255269 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020183879 | NHSA |
| 合肥国高药业有限公司 | 国药准字H20264267 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020183883 | NHSA |
| 湖南慧泽生物医药科技有限公司 | 国药准字H20255982 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020183916 | NHSA |
| 嘉亨(珠海横琴)医药科技有限公司 | 国药准字H20255912 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001020184183 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264139 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020184221 | NHSA |
| 沐源(安徽)药业有限公司 | 国药准字H20255997 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020184519 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20244707 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020200177 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253694 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001020201467 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264857 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020202877 | NHSA |
| 合肥立方制药股份有限公司 | 国药准字H20264453 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020204394 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20253642 | 按美阿沙坦(C30H24N4O8计80 mg | Category B (乙) | XC09CAM175A001020205206 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20264262 | 按C₃₀H₂₄N₄O₈计40mg | Category B (乙) | XC09CAM175A001020205805 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254939 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020209568 | NHSA |
| 江苏永安制药有限公司 | 国药准字H20255786 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40mg | Category B (乙) | XC09CAM175A001020279289 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256242 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020283033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020283521 | NHSA |
| 杭州和泽坤元药业有限公司 | 国药准字H20255269 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020283879 | NHSA |
| 合肥国高药业有限公司 | 国药准字H20264267 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020283883 | NHSA |
| 湖南慧泽生物医药科技有限公司 | 国药准字H20255982 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020283916 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253694 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001020301467 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264857 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020302877 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254939 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020309568 | NHSA |
| 江苏永安制药有限公司 | 国药准字H20255786 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计40mg | Category B (乙) | XC09CAM175A001020379289 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256242 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020383033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020383521 | NHSA |
| 合肥国高药业有限公司 | 国药准字H20264267 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020383883 | NHSA |
| 湖南慧泽生物医药科技有限公司 | 国药准字H20255982 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020383916 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20253694 | 按美阿沙坦(C₃₀H₂₄N₄O₈)计80mg | Category B (乙) | XC09CAM175A001020401467 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20264857 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020402877 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256242 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020483033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020483521 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20256242 | 40mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001020583033 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001020983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001021983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001022983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001023983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001024083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001024183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001024283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001024383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20265038 | 按C₃₀H₂₄N₄O₈计80mg | Category B (乙) | XC09CAM175A001024483521 | NHSA |
| 陕西白鹿制药股份有限公司 | 国药准字H20264152 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001030102353 | NHSA |
| 陕西白鹿制药股份有限公司 | 国药准字H20264152 | 80mg(按C₃₀H₂₄N₄O₈计) | Category B (乙) | XC09CAM175A001030202353 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 33 filings and 17 distinct first applicants.
Generic 33
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 重庆世森医药科技有限公司;烟台鲁银药业有限公司 | CYHS2504395 | Generic | 2025/12/25 | Not stated by source | CDE |
| 重庆世森医药科技有限公司;烟台鲁银药业有限公司 | CYHS2504394 | Generic | 2025/12/25 | Not stated by source | CDE |
| 山东鲁抗医药股份有限公司 | CYHS2504274 | Generic | 2025/12/13 | Not stated by source | CDE |
| 山东鲁抗医药股份有限公司 | CYHS2504273 | Generic | 2025/12/13 | Not stated by source | CDE |
| 杭州端本医药科技有限公司;南京海纳制药有限公司 | CYHS2600864 | Generic | 2026/04/15 | Not stated by source | CDE |
| 杭州端本医药科技有限公司;南京海纳制药有限公司 | CYHS2600863 | Generic | 2026/04/15 | Not stated by source | CDE |
| 江西远盛药业有限公司;江苏永安制药有限公司 | CYHS2503078 | Generic | 2025/08/22 | Not stated by source | CDE |
| 江西远盛药业有限公司;江苏永安制药有限公司 | CYHS2503077 | Generic | 2025/08/22 | Not stated by source | CDE |
| 国药集团容生制药有限公司;江苏永安制药有限公司 | CYHS2502254 | Generic | 2025/06/23 | Not stated by source | CDE |
| 国药集团容生制药有限公司;江苏永安制药有限公司 | CYHS2502252 | Generic | 2025/06/23 | Not stated by source | CDE |
| 南京正科医药股份有限公司 | CYHS2503171 | Generic | 2025/08/29 | Not stated by source | CDE |
| 南京正科医药股份有限公司 | CYHS2503170 | Generic | 2025/08/29 | Not stated by source | CDE |
| 江苏天士力帝益药业有限公司 | CYHS2502864 | Generic | 2025/08/08 | Not stated by source | CDE |
| 江苏天士力帝益药业有限公司 | CYHS2502863 | Generic | 2025/08/08 | Not stated by source | CDE |
| 苏州弘森药业股份有限公司 | CYHS2601306 | Generic | 2026/06/04 | Not stated by source | CDE |
| 苏州弘森药业股份有限公司 | CYHS2601305 | Generic | 2026/06/04 | Not stated by source | CDE |
| 江苏中邦制药有限公司 | CYHS2601009 | Generic | 2026/04/30 | Not stated by source | CDE |
| 江苏中邦制药有限公司 | CYHS2601008 | Generic | 2026/04/30 | Not stated by source | CDE |
| 广东方盛健盟药业有限公司;湖南方盛制药股份有限公司 | CYHS2601133 | Generic | 2026/05/14 | Not stated by source | CDE |
| 山东新华制药股份有限公司;新华制药（高密）有限公司 | CYHS2600324 | Generic | 2026/01/31 | Not stated by source | CDE |
| 山东新华制药股份有限公司;新华制药（高密）有限公司 | CYHS2600323 | Generic | 2026/01/31 | Not stated by source | CDE |
| 石家庄格瑞药业有限公司 | CYHS2600215 | Generic | 2026/01/20 | Not stated by source | CDE |
| 石家庄格瑞药业有限公司 | CYHS2600214 | Generic | 2026/01/20 | Not stated by source | CDE |
| 海森生物医药有限公司;西安杨森制药有限公司 | CYHS2600120 | Generic | 2026/01/09 | Not stated by source | CDE |
| 海森生物医药有限公司;西安杨森制药有限公司 | CYHS2600119 | Generic | 2026/01/09 | Not stated by source | CDE |
| 山东信谊制药有限公司 | CYHS2600103 | Generic | 2026/01/09 | Not stated by source | CDE |
| 山东信谊制药有限公司 | CYHS2600102 | Generic | 2026/01/09 | Not stated by source | CDE |
| 郑州韩都药业集团有限公司 | CYHS2504303 | Generic | 2025/12/17 | Not stated by source | CDE |
| 郑州韩都药业集团有限公司 | CYHS2504302 | Generic | 2025/12/17 | Not stated by source | CDE |
| 福建东瑞制药有限公司 | CYHS2502949 | Generic | 2025/08/13 | Not stated by source | CDE |
| 福建东瑞制药有限公司 | CYHS2502948 | Generic | 2025/08/13 | Not stated by source | CDE |
| 海南葫芦娃药业集团股份有限公司 | CYHS2501311 | Generic | 2025/04/07 | Not stated by source | CDE |
| 海南葫芦娃药业集团股份有限公司 | CYHS2501310 | Generic | 2025/04/07 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 15 filings and 8 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 杭州端本医药科技有限公司;南京海纳制药有限公司 | CYHS2600864 | Generic | 2026/04/15 | Not stated by source | CDE |
| 杭州端本医药科技有限公司;南京海纳制药有限公司 | CYHS2600863 | Generic | 2026/04/15 | Not stated by source | CDE |
| 苏州弘森药业股份有限公司 | CYHS2601306 | Generic | 2026/06/04 | Not stated by source | CDE |
| 苏州弘森药业股份有限公司 | CYHS2601305 | Generic | 2026/06/04 | Not stated by source | CDE |
| 江苏中邦制药有限公司 | CYHS2601009 | Generic | 2026/04/30 | Not stated by source | CDE |
| 江苏中邦制药有限公司 | CYHS2601008 | Generic | 2026/04/30 | Not stated by source | CDE |
| 广东方盛健盟药业有限公司;湖南方盛制药股份有限公司 | CYHS2601133 | Generic | 2026/05/14 | Not stated by source | CDE |
| 山东新华制药股份有限公司;新华制药（高密）有限公司 | CYHS2600324 | Generic | 2026/01/31 | Not stated by source | CDE |
| 山东新华制药股份有限公司;新华制药（高密）有限公司 | CYHS2600323 | Generic | 2026/01/31 | Not stated by source | CDE |
| 石家庄格瑞药业有限公司 | CYHS2600215 | Generic | 2026/01/20 | Not stated by source | CDE |
| 石家庄格瑞药业有限公司 | CYHS2600214 | Generic | 2026/01/20 | Not stated by source | CDE |
| 海森生物医药有限公司;西安杨森制药有限公司 | CYHS2600120 | Generic | 2026/01/09 | Not stated by source | CDE |
| 海森生物医药有限公司;西安杨森制药有限公司 | CYHS2600119 | Generic | 2026/01/09 | Not stated by source | CDE |
| 山东信谊制药有限公司 | CYHS2600103 | Generic | 2026/01/09 | Not stated by source | CDE |
| 山东信谊制药有限公司 | CYHS2600102 | Generic | 2026/01/09 | Not stated by source | CDE |
API registrations
Non-component matches: 13 companies with A status and 15 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 美阿沙坦钾 | 浙江赛默制药有限公司 | Y20240001486 | I | Exact ingredient | 2026/07/07 | CDE |
| 美阿沙坦钾 | 兰州东瑞制药有限公司 | Y20260000472 | I | Exact ingredient | 2026/06/12 | CDE |
| 美阿沙坦钾 | INIST ST Co., Ltd. | Y20250001453 | I | Exact ingredient | 2026/05/12 | CDE |
| 美阿沙坦钾 | 许昌恒生制药有限公司 | Y20260000355 | I | Exact ingredient | 2026/05/08 | CDE |
| 美阿沙坦钾 | 徐州万邦金桥制药有限公司 | Y20260000112 | I | Exact ingredient | 2026/02/28 | CDE |
| 美阿沙坦钾 | 山东信谊制药有限公司 | Y20250001339 | I | Exact ingredient | 2026/01/06 | CDE |
| 美阿沙坦钾 | 安徽艾立德制药有限公司 | Y20250001148 | I | Exact ingredient | 2025/11/11 | CDE |
| 美阿沙坦钾 | 山东益康药业股份有限公司 | Y20250001028 | I | Exact ingredient | 2025/10/10 | CDE |
| 美阿沙坦钾 | 浙江华海药业股份有限公司 | Y20250001040 | I | Exact ingredient | 2025/10/10 | CDE |
| 美阿沙坦钾 | 石家庄格瑞药业有限公司 | Y20250000545 | I | Exact ingredient | 2025/09/05 | CDE |
| 美阿沙坦钾 | 福安药业集团宁波天衡制药有限公司 | Y20250000521 | I | Exact ingredient | 2025/06/06 | CDE |
| 美阿沙坦钾 | 湖南方盛制药股份有限公司 | Y20250000392 | I | Exact ingredient | 2025/05/15 | CDE |
| 美阿沙坦钾 | 苏州盛达药业有限公司 | Y20250000329 | A | Exact ingredient | 2026/10/10 | CDE |
| 美阿沙坦钾 | Zydus Takeda Healthcare Pvt. Ltd. | Y20250000342 | I | Exact ingredient | 2025/04/14 | CDE |
| 美阿沙坦钾 | 浙江天宇药业股份有限公司 | Y20240001145 | A | Exact ingredient | 2026/06/17 | CDE |
| 美阿沙坦钾 | 安徽尖峰北卡药业有限公司 | Y20240000741 | A | Exact ingredient | 2026/05/07 | CDE |
| 美阿沙坦钾 | 合肥立方制药股份有限公司 | Y20240001141 | A | Exact ingredient | 2026/04/21 | CDE |
| 美阿沙坦钾 | 山东新时代药业有限公司 | Y20240001210 | A | Exact ingredient | 2026/07/01 | CDE |
| 美阿沙坦钾 | 长春海悦药业股份有限公司 | Y20240000946 | I | Exact ingredient | 2025/07/18 | CDE |
| 美阿沙坦钾 | 河北国龙制药有限公司 | Y20240000905 | A | Exact ingredient | 2026/11/08 | CDE |
| 美阿沙坦钾 | 齐鲁制药有限公司 | Y20240000577 | A | Exact ingredient | 2025/09/30 | CDE |
| 美阿沙坦钾 | 河北安健成益医药科技有限公司 | Y20240000498 | A | Exact ingredient | 2025/12/04 | CDE |
| 美阿沙坦钾 | 武汉瑞晟药业有限公司 | Y20240000076 | A | Exact ingredient | 2025/07/11 | CDE |
| 美阿沙坦钾 | 重庆圣华曦药业股份有限公司 | Y20240000038 | A | Exact ingredient | 2026/01/31 | CDE |
| 美阿沙坦钾 | 江西同和药业股份有限公司 | Y20220001325 | A | Exact ingredient | 2026/05/20 | CDE |
| 美阿沙坦钾 | 河北仁合益康药业有限公司 | Y20220000775 | I | Exact ingredient | 2023/12/26 | CDE |
| 美阿沙坦钾 | 珠海润都制药股份有限公司 | Y20220000492 | A | Exact ingredient | 2025/05/17 | CDE |
| 美阿沙坦钾 | 山东朗诺制药有限公司 | Y20220000851 | A | Exact ingredient | 2026/09/18 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03No longer listed under review
天津华津制药有限公司
CYHS2502760
Fact date: 2026/11/03 · Site observation date: 2026/11/03
Accepted: 2025/07/31
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Azilsartan Medoxomil Potassium Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy